Zhitong Financial App News, Lai Kai Pharmaceutical-B (02105.HK) announced that the new drug marketing application (NDA) for LAE002 (afuresertib) has been accepted by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) to treat patients with recurrent or progressive disease (LA/c) with previous endocrine (with or without CDK4/6 inhibitors) treatment, accompanied by any PIK3CA/AKT1/PTEN changes.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.